new glp 1 med Eli Lilly to seek approval of GLP-1 weight-loss drug this year Noom Launches GLP-1 Microdosing for

Statements Author contributions QD, MC, JS, and YY researched data for the review, wrote and revised the manuscript, contributed substantially to discussions of its content, and undertook review and editing of the manuscript before submission

Patient assistance programs For those who qualify, both Novo Nordisk and Eli Lilly offer Patient Assistance Programs (PAP) that provide free or reduced-cost medications

Common side effects of weight loss drugs include gastrointestinal issues, increased heart rate, insomnia, and potential dependency

The Problem of Over-Basalization Uptitrating basal insulin is no longer having an HbA1c-lowering effect, while higher insulin doses mean greater risk of weight gain and hypoglycemia

Aequita Pharmacy Mochi Health works with Aequita Pharmacy, a reputable 503A sterile compounding facility

While genetic variants cannot predict exact GLP-1 medication response, understanding your genetic background in peptide and metabolic pathways can support a more nuanced conversation with your healthcare provider about personalized treatment expectations and monitoring strategies